1e
19
1
49
2
2
18
1b
1d
18
33
45
1d
2 29
1d
25
Corey T McMillan, PhD
88
45
Associate Professor of Neurology
28
8e
3
60
Member, Institute for Translational Medicine & Therapeutics, University of Pennsylvania
81
Member, Penn Neurodegeneration Genomics Center, University of Pennsylvania
63
Member, MindCORE, University of Pennsylvania
bd
Fellow, Penn Institute on Aging, Division of Clinical and Translational Neurodegenerative Disease Research, University of Pennsylvania
8e
Co-Director, Penn Frontotemporal Degeneration Center (FTDC), University of Pennsylvania
86
Senior Fellow, Institute for Biomedical Informatics, University of Pennsylvania
8e
Research Associate, Population Aging Research Center (PARC), University of Pennsylvania
88
Faculty Liason, Biomedical Postdoctoral Program (BPP), University of Pennsylvania
11
Department: Neurology
4
1
23
1f
Graduate Group Affiliations
8
b
-
64
- Neuroscience e
1d
46
Contact information
64
4
3
3
1d
64
University of Pennsylvania Perelman School of Medicine
1f Department of Neurology
1a 3400 Spruce Street
2f 3 West Gates
Philadelphia, PA 19104
26
1f Department of Neurology
1a 3400 Spruce Street
2f 3 West Gates
Philadelphia, PA 19104
2e
Office: 215 614 0987
32 Fax: 215 349 8464
32 Lab: 215 349 5863
18
9f
12
32 Fax: 215 349 8464
32 Lab: 215 349 5863
18
18
Publications
23 a
3
2
29
4
b
1f
23 a
13
Education:
21 7 BA 30 (Psychology & Cognitive Neuroscience) c
2a Temple University, 2000.
21 8 MSc 1e (Psycholinguistics) c
30 University of Edinburgh, 2004.
21 8 PhD 17 (Psychology) c
30 University of Edinburgh, 2008.
c
3
3
3
3
8b
Permanent link21 7 BA 30 (Psychology & Cognitive Neuroscience) c
2a Temple University, 2000.
21 8 MSc 1e (Psycholinguistics) c
30 University of Edinburgh, 2004.
21 8 PhD 17 (Psychology) c
30 University of Edinburgh, 2008.
c
2 29
21
1e
1d
24
76
3ce The overall mission of my integrative neuroscience lab is to use multimodal and bioinformatic approaches to improve our understanding of the biological basis of neurodegenerative conditions. My lab aims to develop robust biomarkers that can be used to better diagnose neurodegenerative diseases, accelerate drug discovery of disease-modifying agents, and to define essential clinical trial endpoint measures. My clinical-translation research program focuses on two classes of neurodegenerative proteinopathies including the misfolded tau protein that contributes to Alzheimer’s disease (AD), primary age-related tauopathy (PART), and frontotemporal lobar degeneration (FTLD), as well as the TDP-43 protein that contributes to a spectrum of FTLD and amyotrophic lateral sclerosis (ALS). My lab emphasizes biologically-grounded hypotheses with novel analytic and multimodal approaches integrating MRI and PET imaging modalities with genomics and clinical datasets.
8
12 Keywords:
96 neurodegeneration, neuroimaging, biomarkers, frontotemporal degeneration (FTD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS).
8
1c Rotation Projects:
149 Typical projects involve analysis of neuroimaging datasets to address clinical translation questions (e.g., Can diffusion tensor imaging identify underlying sources of pathology in neurodegenerative disease patients?) or basic science questions (e.g., How is a genetic polymorphism related to neuroanatomical structure?).
8
18 Lab Personnel:
5b All lab personnel are members of the Penn Frontotemporal Degeneration Center (FTDC).
e 29
27
Description of Research Expertise
25 Research Interests:3ce The overall mission of my integrative neuroscience lab is to use multimodal and bioinformatic approaches to improve our understanding of the biological basis of neurodegenerative conditions. My lab aims to develop robust biomarkers that can be used to better diagnose neurodegenerative diseases, accelerate drug discovery of disease-modifying agents, and to define essential clinical trial endpoint measures. My clinical-translation research program focuses on two classes of neurodegenerative proteinopathies including the misfolded tau protein that contributes to Alzheimer’s disease (AD), primary age-related tauopathy (PART), and frontotemporal lobar degeneration (FTLD), as well as the TDP-43 protein that contributes to a spectrum of FTLD and amyotrophic lateral sclerosis (ALS). My lab emphasizes biologically-grounded hypotheses with novel analytic and multimodal approaches integrating MRI and PET imaging modalities with genomics and clinical datasets.
8
12 Keywords:
96 neurodegeneration, neuroimaging, biomarkers, frontotemporal degeneration (FTD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS).
8
1c Rotation Projects:
149 Typical projects involve analysis of neuroimaging datasets to address clinical translation questions (e.g., Can diffusion tensor imaging identify underlying sources of pathology in neurodegenerative disease patients?) or basic science questions (e.g., How is a genetic polymorphism related to neuroanatomical structure?).
8
18 Lab Personnel:
5b All lab personnel are members of the Penn Frontotemporal Degeneration Center (FTDC).
e 29
23
109 McMillan, C. T., Toledo, J., Avants, B., Cook, P., Wood, E. M., Suh, E., Irwin, D. J., Powers, J., Olm, C., Elman, L., McCluskey, L., Schellenberg, G., Lee, V. M.-Y., Trojanowski, J. Q., Van Deerlin, V. M., & Grossman, M. a6 : Genetic & neuroanatomic associations in sporadic frontotemporal lobar degeneration. Neurobiology of Aging 35(6): 1473-1482, Jun 2014.
197 McMillan, C. T., Irwin, D. J., Avants, B. B., Powers, J, Cook, P. A., Toledo, J. B., Wood, E. M., Van Deerlin, V. M., Lee, V. M.-Y., Trojanowski, J. Q., & Grossman, M.: White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery & Psychiatry 84(9): 949-955, Sep 2013.
143 McMillan, C. T., Avants, B., Irwin, D. J., Toledo, J. B., Wolk, D. A., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J Q., & Grossman, M.: Can MRI screen for cerebrospinal fluid biomarkers in neurodegenerative disease? Neurology 80(2): 132-138, 2013.
147 McMillan C. T., Brun, C., Siddiqui, S., Churgin, M., Yushkevich, P., Zhang, H., Libon, D., Gee, J., & Grossman, M.: White matter imaging contributes to the multimodal diagnosis of frontotemporal lobar degeneration. Neurology 78(22): 1761-1768, May 2012.
82 Cook, P. A., McMillan, C. T., Avants, B. B., Peelle, J. E., Gee, J. C., & Grossman, M. 9b : Relating brain anatomy and cognitive ability using a multivariate multimodal framework. NeuroImage 99: 477-486, Oct 2014.
19f Russ, J., Liu, E.Y., Wu, K., Neal, D., Suh, E., Irwin, D. J., McMillan, C. T., Harms, M. B., Cairns, N. J., Wood, E. M., Xie, S. X., Elman, L., McCluskey, L., Grossman, M., Van Deerlin V. M., & Lee, E. B.: Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathologica 129(1): 39-52, Jan 2015.
258 Irwin, D. J., McMillan, C. T., Brettschneider, J., Libon, D. J., Powers, J., Rascovsky, K., Toledo, J. B., Boller, A., Bekisz, J., Chandrasekaran, K., Wood, E. M., Shaw, L., Woo, J. H., Cook, P. A., Wolk, D. A., Arnold, S. E., Van Deerlin, V. M., McCluskey, L. F., Elman, L., Lee, V. M.-Y., Trojanowski, J. Q., & Grossman, M.: Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 84(2): 163-169, Feb 2013.
193 Irwin, D., McMillan, C. T., Toledo, J. B., Arnold, S. E., Shaw, L. M., Wang, L.-S., Lee, V.-Y., Trojanowski, J. Q., & Grossman, M.: Comparison of cerebrospinal fluid levels of tau and Abeta1-42 in Alzheimer's disease and frontotemporal degeneration using two analytical platforms. Archives of Neurology 69(8): 1018-1025, Aug 2012.
181 Irwin, D. J., McMillan, C. T., Suh, E., Powers, J., Rascovsky, K., Wood, E. M., Toledo, J. B., Arnold, S. E., Lee, V. M., Van Deerlin, V. M., Trojanowski, J. Q., & Grossman, M.: Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia. Neurology 83(6): 502-509, Aug 2014.
122 McMillan, C. T., Rascovsky, K., Khella, M. C., Clark, R., & Grossman, M.: The neural basis of establishing a focal point in pure coordination games. Social, Cognitive, & Affective Neuroscience 7(8): 881-887, Nov 2012.
2c
7
1d
1f
Selected Publications
11d McMillan, C. T., Avants, B. B., Cook, P., Ungar, L., Trojanowski, J. Q., & Grossman, M.: The power of neuroimaging biomarkers for screening frontotemporal dementia. Human Brain Mapping 35(9): 4827-4840, Sep 2014.109 McMillan, C. T., Toledo, J., Avants, B., Cook, P., Wood, E. M., Suh, E., Irwin, D. J., Powers, J., Olm, C., Elman, L., McCluskey, L., Schellenberg, G., Lee, V. M.-Y., Trojanowski, J. Q., Van Deerlin, V. M., & Grossman, M. a6 : Genetic & neuroanatomic associations in sporadic frontotemporal lobar degeneration. Neurobiology of Aging 35(6): 1473-1482, Jun 2014.
197 McMillan, C. T., Irwin, D. J., Avants, B. B., Powers, J, Cook, P. A., Toledo, J. B., Wood, E. M., Van Deerlin, V. M., Lee, V. M.-Y., Trojanowski, J. Q., & Grossman, M.: White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery & Psychiatry 84(9): 949-955, Sep 2013.
143 McMillan, C. T., Avants, B., Irwin, D. J., Toledo, J. B., Wolk, D. A., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J Q., & Grossman, M.: Can MRI screen for cerebrospinal fluid biomarkers in neurodegenerative disease? Neurology 80(2): 132-138, 2013.
147 McMillan C. T., Brun, C., Siddiqui, S., Churgin, M., Yushkevich, P., Zhang, H., Libon, D., Gee, J., & Grossman, M.: White matter imaging contributes to the multimodal diagnosis of frontotemporal lobar degeneration. Neurology 78(22): 1761-1768, May 2012.
82 Cook, P. A., McMillan, C. T., Avants, B. B., Peelle, J. E., Gee, J. C., & Grossman, M. 9b : Relating brain anatomy and cognitive ability using a multivariate multimodal framework. NeuroImage 99: 477-486, Oct 2014.
19f Russ, J., Liu, E.Y., Wu, K., Neal, D., Suh, E., Irwin, D. J., McMillan, C. T., Harms, M. B., Cairns, N. J., Wood, E. M., Xie, S. X., Elman, L., McCluskey, L., Grossman, M., Van Deerlin V. M., & Lee, E. B.: Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathologica 129(1): 39-52, Jan 2015.
258 Irwin, D. J., McMillan, C. T., Brettschneider, J., Libon, D. J., Powers, J., Rascovsky, K., Toledo, J. B., Boller, A., Bekisz, J., Chandrasekaran, K., Wood, E. M., Shaw, L., Woo, J. H., Cook, P. A., Wolk, D. A., Arnold, S. E., Van Deerlin, V. M., McCluskey, L. F., Elman, L., Lee, V. M.-Y., Trojanowski, J. Q., & Grossman, M.: Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 84(2): 163-169, Feb 2013.
193 Irwin, D., McMillan, C. T., Toledo, J. B., Arnold, S. E., Shaw, L. M., Wang, L.-S., Lee, V.-Y., Trojanowski, J. Q., & Grossman, M.: Comparison of cerebrospinal fluid levels of tau and Abeta1-42 in Alzheimer's disease and frontotemporal degeneration using two analytical platforms. Archives of Neurology 69(8): 1018-1025, Aug 2012.
181 Irwin, D. J., McMillan, C. T., Suh, E., Powers, J., Rascovsky, K., Wood, E. M., Toledo, J. B., Arnold, S. E., Lee, V. M., Van Deerlin, V. M., Trojanowski, J. Q., & Grossman, M.: Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia. Neurology 83(6): 502-509, Aug 2014.
122 McMillan, C. T., Rascovsky, K., Khella, M. C., Clark, R., & Grossman, M.: The neural basis of establishing a focal point in pure coordination games. Social, Cognitive, & Affective Neuroscience 7(8): 881-887, Nov 2012.
2c